Physician profile
Arie Szatkowski
NPI 1356443451
$12,533.12
in general payments reported to CMS, 2019-2025
39 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,132 · 2020: $1,640 · 2021: $456 · 2022: $1,404 · 2023: $1,637 · 2024: $2,206 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Education: $21.70 · Travel and Lodging: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,873.63 |
| Education | $21.70 |
| Travel and Lodging | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,260.29 | 2019-2020 | |
| Amgen INC. | $905.46 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $665.00 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Medtronic, INC. | $625.12 | 2022-2025 | Symplicity G3, Onyx Frontier, Aurora Ev-Icd Mri Surescan |
| Merck Sharp & Dohme LLC | $607.06 | 2023-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $579.17 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Pfizer INC. | $555.60 | 2019-2025 | |
| Philips North America LLC | $417.88 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Novartis Pharmaceuticals Corporation | $400.76 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $386.53 | 2022-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $373.90 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $364.22 | 2022-2024 | Confirm Rx, Cardiomems |
| Janssen Pharmaceuticals, INC | $354.00 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $285.47 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $273.53 | 2019-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $269.26 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.13 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.75 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $217.50 | 2019-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $212.03 | 2023-2025 | |
| Esperion Therapeutics, INC. | $167.83 | 2022-2025 | Nexletol |
| Biotronik INC. | $144.01 | 2025 | Pamira, Biomonitor, Amvia Edge |
| Kaneka Medical America LLC | $123.01 | 2025 | Apheresis Machine |
| Amarin Pharma, INC. | $114.24 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $99.80 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $99.72 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $81.60 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $67.10 | 2022-2023 | Livalo, Seglentis |
| Portola Pharmaceuticals, LLC | $64.19 | 2019 | |
| Daiichi Sankyo INC. | $63.42 | 2023-2025 | Injectafer |
| Irhythm Technologies, INC. | $49.55 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Arbor Pharmaceuticals, INC. | $46.71 | 2019 | |
| Bardy Diagnostics, INC. | $45.00 | 2021-2022 | |
| Inspire Medical Systems, INC. | $35.01 | 2025 | Inspire |
| Baxter Healthcare | $25.41 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Edwards Lifesciences Corporation | $23.84 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $20.58 | 2023 | Optimizer |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2019 | |
| Gilead Sciences, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arie Szatkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.